Collection of Czechoslovak Chemical Communications - digital archive 

Crossref Cited-by Linking

• Stein Richard A., Gomaa Faris E., Raparla Pranaya, Riber Leise: Now and then in eukaryotic DNA methylation. Physiological Genomics 2024, 56, 741. <https://doi.org/10.1152/physiolgenomics.00091.2024>
• Šimoničová Kristína, Janotka Ľuboš, Kavcová Helena, Sulová Zdena, Breier Albert, Messingerova Lucia: Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Drug Resistance Updates 2022, 61, 100805. <https://doi.org/10.1016/j.drup.2022.100805>
• Janotka Ľuboš, Messingerová Lucia, Šimoničová Kristína, Kavcová Helena, Elefantová Katarína, Sulová Zdena, Breier Albert: Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents. IJMS 2021, 22, 2076. <https://doi.org/10.3390/ijms22042076>
• Sorrentino Vincent G., Thota Srijan, Gonzalez Edward A., Rameshwar Pranela, Chang Victor T., Etchegaray Jean-Pierre: Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia. Pharmaceuticals 2021, 14, 641. <https://doi.org/10.3390/ph14070641>
• Xavier Pedro Luiz Porfirio, Müller Susanne, Fukumasu Heidge: Epigenetic Mechanisms in Canine Cancer. Front. Oncol. 2020, 10. <https://doi.org/10.3389/fonc.2020.591843>
• Wang Chun-Chun, Chen Xing: A Unified Framework for the Prediction of Small Molecule–MicroRNA Association Based on Cross-Layer Dependency Inference on Multilayered Networks. J. Chem. Inf. Model. 2019, 59, 5281. <https://doi.org/10.1021/acs.jcim.9b00667>
• Ganesan A., Arimondo Paola B., Rots Marianne G., Jeronimo Carmen, Berdasco María: The timeline of epigenetic drug discovery: from reality to dreams. Clin Epigenet 2019, 11. <https://doi.org/10.1186/s13148-019-0776-0>
• Alam Mohammad Afaque, Datta Prasun K.: Epigenetic Regulation of Excitatory Amino Acid Transporter 2 in Neurological Disorders. Front. Pharmacol. 2019, 10. <https://doi.org/10.3389/fphar.2019.01510>
• Daifuku Richard, Hu Zhenbo, Saunthararajah Yogen: 5-aza-2′,2′-Difluoro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer. Pharmaceuticals 2017, 10, 65. <https://doi.org/10.3390/ph10030065>
• Shelton Jadd, Lu Xiao, Hollenbaugh Joseph A., Cho Jong Hyun, Amblard Franck, Schinazi Raymond F.: Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. Chem. Rev. 2016, 116, 14379. <https://doi.org/10.1021/acs.chemrev.6b00209>
• Curran Monique P.: Decitabine: A Review of its Use in Older Patients with Acute Myeloid Leukaemia. Drugs Aging 2013, 30, 447. <https://doi.org/10.1007/s40266-013-0084-x>
• Karahoca Metin, Momparler Richard L: Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenet 2013, 5. <https://doi.org/10.1186/1868-7083-5-3>
• Bryan Jeffrey, Kantarjian Hagop, Jabbour Elias: Decitabine for the treatment of acute myeloid leukemia. Expert Opinion on Orphan Drugs 2013, 1, 661. <https://doi.org/10.1517/21678707.2013.819288>
• Thomas Xavier, Heiblig Mael, Bozzoli Valentina, Elhamri Mohamed: Decitabine for the Treatment of Adult Patients (Age ≥65 Years) with Newly Diagnosed De Novo or Secondary Acute Myeloid Leukemia. Int. J. Hematol. Oncol. 2013, 2, 305. <https://doi.org/10.2217/ijh.13.36>
• Thomas Xavier: DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. Expert Opinion on Drug Discovery 2012, 7, 1039. <https://doi.org/10.1517/17460441.2012.722618>
• Marks Peter W: Decitabine for acute myeloid leukemia. Expert Review of Anticancer Therapy 2012, 12, 299. <https://doi.org/10.1586/era.11.207>
• Krečmerová Marcela, Otmar Miroslav: 5-Azacytosine Compounds In Medicinal Chemistry: Current Stage And Future Perspectives. Future Med. Chem. 2012, 4, 991. <https://doi.org/10.4155/fmc.12.36>
• Bryan Jeffrey, Kantarjian Hagop, Garcia-Manero Guillermo, Jabbour Elias: Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opinion on Drug Metabolism & Toxicology 2011, 7, 661. <https://doi.org/10.1517/17425255.2011.575062>
• Goyal Sagun D, Cashen Amanda: Decitabine for the Treatment of Older Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Aging Health 2011, 7, 363. <https://doi.org/10.2217/ahe.11.29>
• Krečmerová Marcela, Masojídková Milena, Holý Antonín: Acyclic nucleoside phosphonates with 5-azacytosine base moiety substituted in C-6 position. Bioorganic & Medicinal Chemistry 2010, 18, 387. <https://doi.org/10.1016/j.bmc.2009.10.044>
• Quintás-Cardama Alfonso, Santos Fabio P. S., Garcia-Manero Guillermo: Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010, 7, 433. <https://doi.org/10.1038/nrclinonc.2010.87>
• Santos Fabio PS, Kantarjian Hagop, Garcia-Manero Guillermo, Issa Jean-Pierre, Ravandi Farhad: Decitabine in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapy 2010, 10, 9. <https://doi.org/10.1586/era.09.164>
• Thomas Xavier, Chelghoum Youcef, Barraco Fiorenza, Troncy Jacques: The rationale and use of hypomethylation agents in adult acute myeloid leukemia. Expert Opinion on Drug Discovery 2009, 4, 195. <https://doi.org/10.1517/17460440802707337>
• Hájek Miroslav, Votruba Ivan, Holý Antonín, Krečmerová Marcela, Tloušt’ová Eva: Alpha anomer of 5-aza-2′-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells. Biochemical Pharmacology 2008, 75, 965. <https://doi.org/10.1016/j.bcp.2007.10.018>
• Dračínský Martin, Krečmerová Marcela, Holý Antonín: Study of chemical stability of antivirally active 5-azacytosine acyclic nucleoside phosphonates using NMR spectroscopy. Bioorganic & Medicinal Chemistry 2008, 16, 6778. <https://doi.org/10.1016/j.bmc.2008.05.058>
• Kurkjian C., Kummar S., Murgo A.J.: DNA Methylation: Its Role in Cancer Development and Therapy. Current Problems in Cancer 2008, 32, 187. <https://doi.org/10.1016/j.currproblcancer.2008.08.002>
• Lavelle Donald, Chin Janet, Vaitkus Kestis, Redkar Sanjeev, Phiasivongsa Pasit, Tang Chunlin, Will Roselle, Hankewych Maria, Roxas Bryan, Singh Mahipal, Saunthararajah Yogen, DeSimone Joseph: Oral decitabine reactivates expression of the methylated γ‐globin gene in Papio anubis. American J Hematol 2007, 82, 981. <https://doi.org/10.1002/ajh.21020>
• Wozniak R J, Klimecki W T, Lau S S, Feinstein Y, Futscher B W: 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 2007, 26, 77. <https://doi.org/10.1038/sj.onc.1209763>
• Atallah Ehab, Kantarjian Hagop, Garcia-Manero Guillermo: The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opinion on Pharmacotherapy 2007, 8, 65. <https://doi.org/10.1517/14656566.8.1.65>
• Liu Zhongfa, Marcucci Guido, Byrd John C., Grever Michael, Xiao Jim, Chan Kenneth K.: Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5‐aza‐2′‐deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Comm Mass Spectrometry 2006, 20, 1117. <https://doi.org/10.1002/rcm.2423>
• Yoo Christine B., Jones Peter A.: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5, 37. <https://doi.org/10.1038/nrd1930>
• de Vos Dick, van Overveld Wendy: Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol 2005, 84. <https://doi.org/10.1007/s00277-005-0008-x>
• Momparler Richard L.: Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Seminars in Hematology 2005, 42, S9. <https://doi.org/10.1053/j.seminhematol.2005.05.002>
• Kantarjian Hagop M., Issa Jean-Pierre J.: Decitabine Dosing Schedules. Seminars in Hematology 2005, 42, S17. <https://doi.org/10.1053/j.seminhematol.2005.05.006>
• de Vos Dick: Epigenetic Drugs: A Longstanding Story. Seminars in Oncology 2005, 32, 437. <https://doi.org/10.1053/j.seminoncol.2005.07.025>
• Wijermans P, Lübbert M: Epigenetic Therapy with Decitabine for Myelodysplasia and Leukemia. Future Oncol. 2005, 1, 585. <https://doi.org/10.2217/14796694.1.5.585>
• Alleman Wade G., Tabios Ray L., Chandramouli Gadisetti V. R., Aprelikova Olga N., Torres-Cabala Carlos, Mendoza Arnulfo, Rodgers Craig, Sopko Nikolai A., Linehan W. Marston, Vasselli James R.: The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2′-deoxycytidine. Clinical Cancer Research 2004, 10, 7011. <https://doi.org/10.1158/1078-0432.CCR-04-0516>
• Dowell Jonathan E., Minna John D.: Cancer Chemotherapy Targeted at Reactivating the Expression of Epigenetically Inactivated Genes. JCO 2004, 22, 1353. <https://doi.org/10.1200/JCO.2004.01.947>
• Leone Giuseppe, Voso Maria Teresa, Teofili Luciana, Lübbert Michael: Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clinical Immunology 2003, 109, 89. <https://doi.org/10.1016/S1521-6616(03)00207-9>
• Pískala Alois, Hanna Naeem B., Masojídková Milena, Otmar Miroslav, Fiedler Pavel, Ubik Karel: Synthesis of N4-Alkyl-5-azacytidines and Their Base-Pairing with Carbamoylguanidines - A Contribution to Explanation of the Mutagenicity of 2'-Deoxy-5-azacytidine. Collect. Czech. Chem. Commun. 2003, 68, 711. <https://doi.org/10.1135/cccc20030711>
• Goffin J., Eisenhauer E.: DNA methyltransferase inhibitors—state of the art. Annals of Oncology 2002, 13, 1699. <https://doi.org/10.1093/annonc/mdf314>
• Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S: Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 2001, 27, 1221. <https://doi.org/10.1038/sj.bmt.1703028>
• Gaubert Gilles, Mathé Christophe, Imbach Jean-Louis, Eriksson Staffan, Vincenzetti Silvia, Salvatori Daniela, Vita Alberto, Maury Georges: Unnatural enantiomers of 5-azacytidine analogues: Syntheses and enzymatic properties. European Journal of Medicinal Chemistry 2000, 35, 1011. <https://doi.org/10.1016/S0223-5234(00)01184-3>
• Thibault Alain, Figg William D., Bergan Raymond C., Lush Richard M., Myers Charles E., Tompkins Anne, Reed Eddie, Samid Dvorit: A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer. Tumori 1998, 84, 87. <https://doi.org/10.1177/030089169808400120>
• Lim Benjamin B., Marquez Victor E., Dobyns Kathryn A., Cooney David A., Clercq Erik De: Synthesis and Biological Study of the Cyclopentenyl Carbocyclic Nucleoside Analogue of 5-Azacytidine. Nucleosides and Nucleotides 1992, 11, 1123. <https://doi.org/10.1080/07328319208018331>
• Daher George C., Harris Barry E., Diasio Robert B.: Metabolism of pyrimidine analogues and their nucleosides. Pharmacology & Therapeutics 1990, 48, 189. <https://doi.org/10.1016/0163-7258(90)90080-L>
• Ben-hattar Jean, Jiricny Josef: Facile Synthesis of Base-Labile 2′-Deoxyribonucleosides: An Improved Synthesis of 2′-Deoxy-5-aza-Cytidine. Nucleosides and Nucleotides 1987, 6, 393. <https://doi.org/10.1080/07328318708056233>
• Moriconi William J., Slavik Milan, Taylor Sarah: 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response. Invest New Drugs 1986, 4, 67. <https://doi.org/10.1007/BF00172020>
• Pochet Sylvie, Huynh-dinh Tam: Amino-4 Dihydroxy-2, 6 (Desoxy-2-D-ribofurannosyl)-1-s-Triazines. Nucleosides and Nucleotides 1986, 5, 153. <https://doi.org/10.1080/07328318608068669>
• Čihák Alois, Vesely̌ Jiří, Sǩoda Jan: Azapyrimidine nucleosides: metabolism and inhibitory mechanisms. Advances in Enzyme Regulation 1985, 24, 335. <https://doi.org/10.1016/0065-2571(85)90085-8>
• Momparler Richard L., Rivard Georges E., Gyger Martin: Clinical trial on 5-AZA-2′-deoxycytidine in patients with acute leukemia. Pharmacology & Therapeutics 1985, 30, 277. <https://doi.org/10.1016/0163-7258(85)90052-X>
• Momparler Richard L.: Molecular, cellular and animal pharmacology of 5-AZA-2′-deoxycytidine. Pharmacology & Therapeutics 1985, 30, 287. <https://doi.org/10.1016/0163-7258(85)90053-1>
• Momparler Richard L., Samson Johanne, Momparler Louise F., Rivard Georges E.: Cell cycle effects and cellular pharmacology of 5-AZA-2?-deoxycytidine. Cancer Chemother. Pharmacol. 1984, 13, 191. <https://doi.org/10.1007/BF00269027>
• Paluska E., Hrubá Alena, Madar J., Činátl J., Chudomel V., Nezvalová Jana, Čihák A.: Inhibitory effects of 5-azapyrimidine nucleosides on cellular immunity. Immunobiology 1982, 162, 288. <https://doi.org/10.1016/S0171-2985(11)80008-2>
• Lin Kun-Tsan, Momparlerm Richard L., Rivard Georges E.: High-performance Liquid Chromatographic Analysis of Chemical Stability of 5-aza-2′-Deoxycytidine. Journal of Pharmaceutical Sciences 1981, 70, 1228. <https://doi.org/10.1002/jps.2600701112>
• Rivard Georges E., Momparler Richard L., Demers Jocelyn, Benoit Paul, Raymond Richard, Lin Kun-Tsan, Momparler Louise F.: Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leukemia Research 1981, 5, 453. <https://doi.org/10.1016/0145-2126(81)90116-8>
• Rada Břetislav, Doskočil Jiři: Azapyrimidine nucleosides. Pharmacology & Therapeutics 1980, 9, 171. <https://doi.org/10.1016/S0163-7258(80)80018-0>
• Veselý Jiří, Čihák Alois: 5-Azacytidine: Mechanism of action and biological effects in mammalian cells. Pharmacology & Therapeutics. Part A: Chemotherapy, Toxicology and Metabolic Inhibitors 1978, 2, 813. <https://doi.org/10.1016/0362-5478(78)90016-5>
• Fuǔík Vladimír, Michaelis Arnd, Rieger Rigomar: On the induction of segment extension and chromatid structural changes in Vicia faba chromosomes after treatment with 5-azacytidine and 5-azadeoxycytidine. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1970, 9, 599. <https://doi.org/10.1016/0027-5107(70)90105-3>
• Vorbrüggen H., Niedballa U.: Eine einfache synthese von 5-azapyrimidin-nucleosiden. Tetrahedron Letters 1970, 11, 3571. <https://doi.org/10.1016/S0040-4039(01)98530-2>
• Doskočil J., ŠOrm F.: The Mode of Action of 5‐Aza‐2′‐Deoxycytidine in Escherichia coli. European Journal of Biochemistry 1970, 13, 180. <https://doi.org/10.1111/j.1432-1033.1970.tb00916.x>
• Bognár R., Somogyi L., Szilágyi L., Györgydeák Z.: N-Glykosyl-Derivate. Carbohydrate Research 1967, 5, 320. <https://doi.org/10.1016/S0008-6215(00)80506-6>